Literature DB >> 2484685

Molecular aspects underlying the vasodilator action of molsidomine.

E Noack1, M Feelisch.   

Abstract

Using different techniques, we measured the kinetics of nitric oxide (NO) liberation from SIN-1, the metabolite of molsidomine, and some related sydnonimines like its thiomorpholinyl analog, compound C 78-0698, and compared it under identical experimental conditions with its biological action at the guanylate cyclase (GC) site, taking this target enzyme as a suitable bioassay. There was a close relationship between half-maximal activation of GC and the velocity of NO release. The thiomorpholinyl analog was slightly more active in NO liberation than SIN-1 and activated the enzyme more rapidly. The kinetics of SIN-1A and SIN-1C formation, determined by high-performance liquid chromatography, could be accurately described by a Bateman equation. Oxyhemoglobin shifted the concentration-response curve of SIN-1 at the isolated soluble GC concentration to the right, whereas methemoglobin was without any effect. The results of our chemical and biochemical studies suggest that velocity and amount of NO formation are the only rate-limiting factors of guanylate cyclase activation by sydnonimines like SIN-1. NO, therefore, exclusively is the mediator of their pharmacodynamic action. In remarkable contrast to nitrate esters like glyceryl trinitrate or isosorbide dinitrate, NO liberation is not dependent on the interaction with thiol-containing compounds like cysteine.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2484685

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  11 in total

1.  In vitro studies of interactions of NO. donor drugs with superoxide and hydroxyl radicals.

Authors:  F Dalloz; V Maupoil; S Lecour; F Briot; L Rochette
Journal:  Mol Cell Biochem       Date:  1997-12       Impact factor: 3.396

2.  Mechanism of anti-proliferation caused by YC-1, an indazole derivative, in cultured rat A10 vascular smooth-muscle cells.

Authors:  S M Yu; Z J Cheng; J H Guh; F Y Lee; S C Kuo
Journal:  Biochem J       Date:  1995-03-15       Impact factor: 3.857

3.  The effects of the nitric oxide donors molsidomine and SIN-I on human polymorphonuclear leucocyte function in vitro and ex vivo.

Authors:  H Darius; L Grodzinska; J Meyer
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

4.  The effects of molsidomine on hypoxia inducible factor alpha and Sonic hedgehog in testicular ischemia/reperfusion injury in rats.

Authors:  Ali Ihsan Dokucu; Hulya Ozturk; Hayrettin Ozturk; Mehmet Cudi Tuncer; Fahri Yilmaz
Journal:  Int Urol Nephrol       Date:  2008-09-12       Impact factor: 2.370

5.  Inhibition of proliferation, but not of Ca2+ mobilization, by cyclic AMP and GMP in rabbit aortic smooth-muscle cells.

Authors:  J W Assender; K M Southgate; M B Hallett; A C Newby
Journal:  Biochem J       Date:  1992-12-01       Impact factor: 3.857

6.  Cytotoxicity of nitric oxide in Fu5 rat hepatoma cells: evidence for co-operative action with hydrogen peroxide.

Authors:  I Ioannidis; H de Groot
Journal:  Biochem J       Date:  1993-12-01       Impact factor: 3.857

7.  Effect of the molsidomine metabolite SIN-1 on coronary arteries and peripheral vessels of sheep with special reference to tolerance and endothelium.

Authors:  M H Yousif; F Yousif; O Thulesius
Journal:  Cardiovasc Drugs Ther       Date:  1991-08       Impact factor: 3.727

8.  S35b, a new phenylsulfonylfuroxan compound, inhibits thrombin-induced synthesis of platelet-activating factor and prostacyclin in human endothelial cells.

Authors:  R Heller; F Bussolino; R Calvino; D Ghigo; P Alessio; R Todde; R Fruttero; G Pescarmona; A Gasco; U Till
Journal:  Agents Actions       Date:  1993-11

9.  Modulation by nitric oxide of prostaglandin biosynthesis in the rat.

Authors:  L Sautebin; A Ialenti; A Ianaro; M Di Rosa
Journal:  Br J Pharmacol       Date:  1995-01       Impact factor: 8.739

10.  Differential effects of the novel NO-donating drug pirsidomine and isosorbide dinitrate on the venous vascular bed.

Authors:  C de Mey; K Breithaupt; M Seibert-Grafe; G G Belz
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.